Company: MVIS
Filing Date: 2025-08-08
Form Type: 10-Q
Source: 0001641172-25-022632
Chunk: 24

Company: MICROVISION, INC.
Filing Date: 2025-08-08
Form: 10-Q
Item: Part I, Item 1
Chunk 24
---

  
    Derivative
    liability 
    $-  
    $-  
    $2,915 
  
    Total 
    $-  
    $-  
    $2,915 

    As
    of December 31, 2024 
    Level
    1  
    Level
    2  
    Level
    3 
  
    Derivative
    liability 
    $-  
    $-  
    $14,581 
  
    Total 
    $-  
    $-  
    $14,581 

The
table below lists the inputs and assumptions for the Company’s valuations as of June 30, 2025 and December 31, 2024:

 SCHEDULE
OF REVALUATION DERIVATIVE LIABILITY

    June
    30,  
    December
    31, 

    2025  
    2024 
  
    Expected
    term (years) 
     1.25  
     1.75 
  
    Risk-free
    interest rate 
     3.86% 
     4.18%
  
    Dividend
    yield 
     0% 
     0%
  
    Volatility 
     88.96% 
     78.02%
  
    Discount
    rate 
     50.0% 
     50.0%

7.
WARRANT LIABILITY

On
February 3, 2025, the Company entered into a new Securities Purchase Agreement (the “2025 Purchase Agreement”) with an institutional
investor. In exchange for $8.0 million, the Holder agreed to purchase 5,750,225 shares of common stock (the “closing shares”)
and warrants to purchase up to 5,750,225 shares of common stock at an exercise price of $1.57 per share (the “warrants”).
On February 4, 2025, the 2025 Purchase Agreement closed for net proceeds of approximately $7.8 million, inclusive of all fees and expenses
related to the transaction. The warrants are exercisable beginning August 4, 2025 and expire on August 4, 2030. There have been no exercises
of warrants as of June 30, 2025.

The
warrants are accounted for as a liability under ASC 480, Distinguishing Liabilities from Equity. Both